---
title: Gentian Diagnostics ASA – Approval and publication of prospectus, and transfer of listing from Euronext Growth (Oslo) to Oslo Børs
description: Gentian Diagnostics ASA – Approval and publication of prospectus, and transfer of listing from Euronext Growth (Oslo) to Oslo Børs
---

Moss, 24 June 2021

Reference is made to the announcement made by Gentian Diagnostics ASA (the "Company") on 7 May 2021 where it was announced that the Company had submitted an application for admission to trading on Oslo Børs (the "Listing") by transfer of its current admission to trading on Euronext Growth Oslo. The application was approved on 23 June 2021.

The first day of trading of the Company's shares on Oslo Børs’ main list is expected to be on 25 June 2021. Consequently, the last day of trading of the Company's shares on Euronext Growth Oslo is expected to be today, 24 June 2021.

The Company has prepared a prospectus in connection with the Listing (the "Prospectus"), which has been approved by the Norwegian Financial Supervisory Authority. The Prospectus is available at:

[www.gentian.com/investor-relations-stock-information/key-information-investors/](https://www.gentian.com/investor-relations-stock-information/key-information-investors/) 

Hard copies of the Prospectus may be obtained free of charge at the Company's registered business address Bjørnåsveien 5, 1596 Moss, Norway (subject to prevailing restrictions due to the Covid-19 pandemic).

AGP Advokater AS has acted as legal counsel to the Company in connection with the Listing and Advokatfirmaet Selmer AS and Moore Consulting AS have acted as due diligence advisors.

**For further information please contact:**  
Hilja Ibert CEO, Gentian Diagnostics  
E-mail: [hilja.ibert@gentian.no](mailto:hilja.ibert@gentian.no)   
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics  
E-mail: [njaal.kind@gentian.no](mailto:njaal.kind@gentian.no)   
Cell Phone. +47 919 06 525

**More information:**  
[Access the news on Oslo Bors NewsWeb site](https://newsweb.oslobors.no/message/536767)

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-asa-approval-and-publication-of-prospectus-and-transfer-of-listing-from-euronext-growth-o-1624528230565#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-asa-approval-and-publication-of-prospectus-and-transfer-of-listing-from-euronext-growth-o-1624528230565#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-asa-approval-and-publication-of-prospectus-and-transfer-of-listing-from-euronext-growth-o-1624528230565#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)